October 26–27 | Dubai
Dr. Alex Aliper, Co-founder and President of Insilico Medicine, has been invited to attend the Dubai AI Festival 2026 at the Dubai World Trade Centre (DWTC). On the afternoon of October 26, from 14:10 to 14:30, he will deliver a keynote speech titled "Generative AI for drug discovery and healthcare delivery" on the Innovation Stage.
As a global leader in AI-driven drug discovery and foundational research, Dr. Alex Aliper will take the stage alongside international business leaders, regulatory authorities, and investors. He will share Insilico Medicine’s real-world insights and practice in leveraging generative AI foundation models to transform the entire chain of target discovery, molecular design, clinical development, and healthcare delivery, further expanding strategic collaboration with the Middle East's AI innovation ecosystem.
About Dubai AI Festival 2026
The Dubai AI Festival is one of the Middle East’s leading AI industry events on a scale and influence. Directed by H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and Minister of Defence, the festival is jointly initiated by the Dubai International Financial Centre (DIFC) and Dubai AI Campus, organized by Terrapinn, and serves as the flagship event of Dubai AI Week. Featuring the Plenary Stage and Innovation Stage across eight core tracks—including AI for All, Global AI Governance, Future of Work, Infrastructure, and Investment—the festival brings together top global AI unicorns, government entities, multinational corporations, and premier venture capital firms to drive meaningful collaboration moving AI from concept to deep industrial implementation.
October 26–27 | Hong Kong
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 2026 Global Healthcare Innovation Summit (GHIS 2026) at the Grand Hyatt Hong Kong. On the afternoon of October 26, from 14:00 to 14:30, he will participate in a panel discussion titled "AI Pharma at an Inflection Point: Technological Innovation and Industry Transformation."
As one of China's leading AI pharma scientists, Dr. Feng Ren will focus on the overarching theme of "Reshaping Global Healthcare Asset Valuations." Joined by global MNCs, listed Chinese companies, high-growth innovative ventures, and international institutional investors, he will explore how generative AI is systematically reshaping the end-to-end drug discovery pipeline across three dimensions: technology, commercialization, and AI innovation. He will also share key industry insights and global collaboration experience accumulated since Insilico Medicine listed on the Hong Kong Stock Exchange as a landmark AI pharma company.
About GHIS 2026
The 2026 Global Healthcare Innovation Summit (GHIS 2026) is hosted by the GHIS International Healthcare Innovation Alliance and organized by MedTrend. Held from October 26 to 27 at the Grand Hyatt Hong Kong under the main theme "Healthcare Innovation and Capital Transactions from a Global Perspective," the summit features an efficient layout combining forums, enterprise roadshows, and 1-on-1 business partnering. Deeply covering four frontier fields—biopharmaceuticals, medical devices, digital health & medical AI, and life sciences—it brings together over 70 global industry leaders, more than 50 investment firms, and over 100 international investors to facilitate over 1,000 targeted business meetings, serving as a benchmark event anchored in Hong Kong as a cross-border hub.
October 28–30 | Seoul
Dr. Jue Wang Global Head of Business Development at Insilico Medicine, has been invited to attend BioPlus-Interphex Korea 2026 (BIX 2026) at COEX in Seoul. On the morning of October 30 at 11:50, she will deliver a keynote presentation at the specialized session titled "We All Have AI. Now What?: Building Real Value in AI Drug Discovery."
On Asia-Pacific’s most representative biopharma industry platform, Dr.Jue will join industry leaders from Korea and around the world to explore the paradigm shift from merely "having AI" to "maximizing AI's value." Drawing on Insilico Medicine’s global track record in out-licensing, co-development, and R&D partnerships, she will share critical factors for scaling AI-driven drug discovery from concept into high-volume outputs.
Additionally, Insilico Medicine will showcase its solutions at Booth BF02, where its BD team will engage with global partners on cutting-edge developments in AI drug discovery, display innovative applications of generative AI across the entire drug lifecycle, and actively seek multi-dimensional strategic partnerships.
About BioPlus-Interphex Korea (BIX 2026)
BioPlus-Interphex Korea (BIX) is the flagship biopharma industry event hosted by the Korea Biotechnology Industry Organization (KoreaBIO) and organized by RX Korea. It unites Korea's premier bio-event, BIOPLUS, with the global INTERPHEX exhibition brand (which spans over 45 years across New York, Tokyo, and beyond), covering the full value chain from drug discovery and development to biomanufacturing and packaging innovation. The 2026 event is expected to attract over 300 exhibitors from 25+ countries, more than 10,000 professional visitors, 36+ thematic sessions, and over 500 business partnering meetings, serving as the core platform for global biopharma companies to enter Korean and Asia-Pacific markets.
October 29 | Suzhou
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 6th SAPA-China 2026 Healthcare Industry Conference at the Suzhou Shishan International Conference Center. On the afternoon of October 29, Dr. Ren will deliver two presentation sessions illustrating Insilico Medicine’s successful journey from "hardcore technology" to "commercialization and capital markets."
First, from 13:30 to 13:50, Dr. Ren will present "AI-Driven Small Molecule R&D from Demo to Pipeline: Target Identification, Molecule Generation, and Experimental Closed-Loop," detailing the real-world application of the Pharma.AI platform across small molecule R&D and revealing the logic behind generative AI empowering preclinical and clinical pipeline development. Later, from 14:55 to 15:20, he will speak at the Investment, Financing & Entrepreneurship Forum on "IPO Fundraising Journey and BD Breakthroughs Amid the Capital Winter." Drawing from Insilico Medicine’s milestone listing on the Main Board of the HKEX in late 2025, he will provide in-depth analysis of financing strategies and BD licensing tactics under challenging market conditions, offering valuable reference points for biopharma technology translation and capital operation.
About SAPA-China 2026 Healthcare Industry Conference
The 6th SAPA-China 2026 Healthcare Industry Conference is hosted by SAPA-China (Sino-American Pharmaceutical Professionals Association), co-organized by the Suzhou Xushuguan Economic and Technological Development Zone Management Committee, and managed by Suzhou Shengjie. Taking place from October 29 to 30 at the Suzhou Shishan International Conference Center, this year's conference features 1 main plenary forum, 14 specialized venues, and 42 parallel sessions. Bringing together top global researchers, executives from MNCs and biotech startups, as well as clinical and investment experts, it focuses on core tracks including small and large molecules, cell and gene therapy, nucleic acid drugs, AI pharma, clinical research, and investment/financing. Expected to attract over 8,000 industry delegates and 400+ experts, it stands as one of China's flagship annual pharma events spanning from source innovation to industrial application.
October 29–30 | Shenzhen
Dr. Alex Aliper, Co-founder and President of Insilico Medicine, has been invited to attend the 2026 Tencent Global Digital Ecosystem Summit , held in Hall 18 at the Shenzhen World Exhibition & Convention Center. On the morning of October 30 at 09:55 AM, Dr. Aliper will deliver a speech titled "Cutting-Edge AI for Drug Discovery and Longevity Research: MMAI Gym and SOTA Models" at the Life Sciences Session.
As a global leader in AI-driven drug discovery and basic research, Dr. Aliper will systematically share Insilico Medicine’s latest practices with MMAI Gym for Science . He will highlight how this training framework is utilized to build state-of-the-art expert models in chemistry and biology, achieving SOTA performance across over 50 benchmark tasks. Furthermore, he will elaborate on how these capabilities drive scalable innovation, enable the discovery of novel molecular entities, and facilitate diversification into broad indications—thereby accelerating drug discovery and longevity research, and serving as an industry-first benchmark for the deep integration of AI and life sciences.
About Tencent Global Digital Ecosystem Summit
The Tencent Global Digital Ecosystem Summit is Tencent’s premier annual strategic event for the industrial internet sector, featuring the highest specifications, largest scale, and broadest coverage. Since its inception in 2019, it has been successfully held for eight consecutive editions.
Dedicated to gathering global intelligence and uncovering new digital opportunities, the summit unveils blueprints for critical technologies such as Cloud, AI, Big Data, and Security, while showcasing Tencent’s latest research achievements, strategic roadmaps, tech products, and industry solutions. Bringing together best industry practices forged by Tencent and its digital ecosystem partners in driving industrial digitalization and digital industrialization, the summit serves as a panoramic window for governments, enterprises, partners, developers, professionals, and the general public to understand Tencent's global digital ecosystem.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com